Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial.

Diabetes Obes Metab · 2025 · PMC12515792 · PMID 40808546

Europe PMC DOI

hedged sentence

0.0890

closest p · 1.8× alpha

0.0890

boldest claim

The sentences

did not reach statistical significancep = 0.0890so close (0.05 < p ≤ 0.1)

Triglyceride level decreased in all groups, with the largest reduction observed in the pioglitazone group (−37.05 ± 9.13 mg/dL), although the differences did not reach statistical significance ( p = 0.0890).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.